EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gut Microbiota Serves as a Crucial Independent Biomarker in Inflammatory Bowel Disease (IBD)

Bharti Sharma iD, George Agriantonis, Kate Twelker iD, Danielle Ebelle, Samantha Kiernan, Maham Siddiqui, Aditi Soni, Sittha Cheerasarn, Whenzdjyny Simon, Winston Jiang, Angie Cardona, Jessica Chapelet und 7 weitere

International Journal of Molecular Sciences · 11.03.2025 · 26 (6) · 2503

DOI: 10.3390/ijms26062503 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 11.03.2025. Verfasst von Bharti Sharma und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, NYC Health and Hospitals-Elmhurst, New York, NY 11373, USA. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 173 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory bowel disease (IBD), encompassing Crohn’s disease (CD), ulcerative colitis (UC), and IBD unclassified (IBD-U), is a complex intestinal disorder influenced by genetic, environmental, and microbial factors. Recent evidence highlights the gut microbiota as a pivotal biomarker and modulator in IBD pathogenesis. Dysbiosis, characterized by reduced microbial diversity and altered composition, is a hallmark of IBD. A consistent decrease in anti-inflammatory bacteria, such as Faecalibacterium prausnitzii, and an increase in pro-inflammatory species, including Escherichia coli, have been observed. Metabolomic studies reveal decreased short-chain fatty acids (SCFAs) and secondary bile acids, critical for gut homeostasis, alongside elevated pro-inflammatory metabolites. The gut microbiota interacts with host immune pathways, influencing morphogens, glycosylation, and podoplanin (PDPN) expression. The disruption of glycosylation impairs mucosal barriers, while aberrant PDPN activity exacerbates inflammation. Additionally, microbial alterations contribute to oxidative stress, further destabilizing intestinal barriers. These molecular and cellular disruptions underscore the role of the microbiome in IBD pathophysiology. Emerging therapeutic strategies, including probiotics, prebiotics, and dietary interventions, aim to restore microbial balance and mitigate inflammation. Advanced studies on microbiota-targeted therapies reveal their potential to reduce disease severity and improve patient outcomes. Nevertheless, further research is needed to elucidate the bidirectional interactions between the gut microbiome and host immune responses and to translate these insights into clinical applications. This review consolidates current findings on the gut microbiota’s role in IBD, emphasizing its diagnostic and therapeutic implications, and advocates for the continued exploration of microbiome-based interventions to combat this debilitating disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeInflammatory Bowel DiseasesHumansBiomarkersDysbiosisAnimals

Stichwörter der Autor:innen

Crohn’s diseaseglycosylationgut microbiotainflammatory bowel diseasemorphogenpodoplaninulcerative colitis

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Surgery, NYC Health and Hospitals-Elmhurst, New York, NY 11373, USA.
  • Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Department of Medicine, St. George's University, Grenada FZ818, West Indies.
  • Department of Medicine, Medical University of the Americas, Devens, MA 01434, USA.

ORCID-Profile: Bharti Sharma, Kate Twelker

Zitieren

APA

Sharma, B., Agriantonis, G., Twelker, K., Ebelle, D., Kiernan, S., Siddiqui, M., Soni, A., Cheerasarn, S., Simon, W., Jiang, W., Cardona, A., Chapelet, J., Agathis, A. Z., Gamboa, A., Dave, J., Mestre, J., Bhatia, N. D., Shaefee, Z., & Whittington, J. (2025). Gut Microbiota Serves as a Crucial Independent Biomarker in Inflammatory Bowel Disease (IBD). International Journal of Molecular Sciences, 26(6), 2503. https://doi.org/10.3390/ijms26062503

Vancouver

Sharma B, Agriantonis G, Twelker K, Ebelle D, Kiernan S, Siddiqui M, et al. Gut Microbiota Serves as a Crucial Independent Biomarker in Inflammatory Bowel Disease (IBD). International Journal of Molecular Sciences. 2025;26(6):2503. doi:10.3390/ijms26062503

BibTeX
@article{Sharma2025,
  author = {Sharma, Bharti and Agriantonis, George and Twelker, Kate and Ebelle, Danielle and Kiernan, Samantha and Siddiqui, Maham and Soni, Aditi and Cheerasarn, Sittha and Simon, Whenzdjyny and Jiang, Winston and Cardona, Angie and Chapelet, Jessica and Agathis, Alexandra Z and Gamboa, Alejandro and Dave, Jasmine and Mestre, Juan and Bhatia, Navin D and Shaefee, Zahra and Whittington, Jennifer},
  title = {Gut Microbiota Serves as a Crucial Independent Biomarker in Inflammatory Bowel Disease (IBD)},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {6},
  pages = {2503},
  doi = {10.3390/ijms26062503}
}
Kostenlos starten →